What Is a Lay Result Letter in Mammography?

Introduction

A lay result letter, also called a lay summary or patient results letter, is the written communication required by the Mammography Quality Standards Act (MQSA) that every certified facility must send directly to the patient. It summarizes the mammography results in plain, easily understood language. Enforcement of the 2023 MQSA Final Rule amendments began on September 10, 2024. These amendments require every lay summary to include a standardized overall assessment of breast density classified into one of four categories, plus one of two exact FDA-prescribed notification statements depending on whether the tissue is dense or not dense. The letter remains distinct from the technical mammography report sent to the healthcare provider. Its clarity, actionability, health-literacy alignment, and emotional tone determine whether patients understand the findings and complete recommended follow-up. [1][2]

Core Regulatory Requirements Under the Amended MQSA

Under 21 CFR 900.12(c)(2), each facility shall provide every patient a summary of the mammography report written in lay terms within 30 calendar days of the mammographic examination. When the final assessment is Suspicious or Highly Suggestive of Malignancy, the facility shall provide the lay summary within 7 calendar days of the final interpretation. A telephone call alone does not satisfy the requirement. The summary must include, at minimum, the patient's name; the name, address, and telephone number of the facility; an overall final assessment of the findings; an overall assessment of breast density; the mandated density notification language; and any recommendations. These rules apply to every patient, including those who are self-referred. For self-referred patients the facility must also send the technical report and maintain a system to refer the patient to a healthcare provider when clinically indicated, including assessments of Probably Benign, Suspicious, or Highly Suggestive of Malignancy. [3][4]

The four density categories required in the report to the healthcare provider are: The breasts are almost entirely fatty; There are scattered areas of fibroglandular density; The breasts are heterogeneously dense, which may obscure small masses; and The breasts are extremely dense, which lowers the sensitivity of mammography. Tissue described as almost entirely fatty or scattered areas of fibroglandular density is treated as not dense. Tissue described as heterogeneously dense or extremely dense is treated as dense. The exact notification statements that must appear in the patient lay summary are fixed by regulation. For not-dense tissue the statement reads: Breast tissue can be either dense or not dense. Dense tissue makes it harder to find breast cancer on a mammogram and also raises the risk of developing breast cancer. Your breast tissue is not dense. Talk to your healthcare provider about breast density, risks for breast cancer, and your individual situation. For dense tissue the statement reads: Breast tissue can be either dense or not dense. Dense tissue makes it harder to find breast cancer on a mammogram and also raises the risk of developing breast cancer. Your breast tissue is dense. In some people with dense tissue, other imaging tests in addition to a mammogram may help find cancers. Talk to your healthcare provider about breast density, risks for breast cancer, and your individual situation. Facilities may add separate explanatory material, but they may not alter the required federal statements. [1][4]

The overall assessment categories used in both the technical report and the corresponding lay summary follow the standardized lexicon that aligns with the American College of Radiology Breast Imaging Reporting and Data System (ACR BI-RADS) framework while satisfying the MQSA regulatory language. These categories include Negative, Benign, Probably Benign, Suspicious, Highly Suggestive of Malignancy, Known Biopsy-Proven Malignancy, Post-Procedure Mammogram for Marker Placement, and the Incomplete designations (Need Additional Imaging Evaluation or Need Prior Mammograms for Comparison). The lay summary translates the chosen category into everyday language so the patient can grasp the clinical meaning and the next required action.

Distinction From the Technical Report and Delivery Mechanics

The technical mammography report travels to the referring healthcare provider (or to the patient if no provider is named). It contains the full interpretive detail, the exact density category wording, and formal recommendations. The lay result letter travels directly to the patient. It is intentionally stripped of specialized terminology so that a person without medical training can process the essential facts. Delivery may occur by hand at the time of the examination, by mail, or by electronic means such as a patient portal or email, provided the required timeline is met. Even when results are Incomplete and additional imaging is needed, the facility must still issue a written lay summary within 30 calendar days that states the need for further evaluation. [4]

Mechanisms That Convert Information Into Patient Action

Three determinants mediate whether the letter produces the intended follow-up. First is health-literacy alignment. Many adults function at basic or below-basic health literacy levels. Letters written above the sixth-to-eighth-grade reading level recommended by federal agencies produce measurable comprehension failures. Nguyen and colleagues demonstrated that lowering the readability of a recall lay letter from approximately twelfth-grade to sixth-grade level raised the 60-day diagnostic follow-up rate from 90.1 percent to 93.9 percent and nearly doubled the odds of timely return after controlling for site. [5]

Second is emotional tone calibration. Excess threat without a clear path forward can trigger avoidance. Balanced framing that conveys moderate urgency together with concrete efficacy supports action. Third is actionability. Vague instructions leave patients unsure who schedules the next appointment, when it should occur, or whom to call. Letters that name the department, supply a direct telephone number, state the expected timeframe, and describe what will happen at the visit close the intention-action gap.

These mechanisms interact. A letter that is readable, appropriately framed, and specifically actionable removes multiple barriers at once. In our experience, facilities that treat the mandatory letter as the single touchpoint leave residual gaps that sequential outreach and navigation can close. The 30-60-90 day written protocol begins with the regulatory letter, then issues progressively more specific reminders at approximately 30, 60, and 90 days for non-responders. Technology enables personalization based on prior response history, language preference, and known barriers. Adding structured telephone contact further increases return rates. Nguyen and colleagues showed that written communication alone produced a 73.1 percent 60-day return rate; the addition of next-business-day telephone outreach raised adherence to 87.6 percent and later to 90.0 percent while shortening median time to imaging from 28 days to 9 days. [6][8]

Tools for Measuring and Improving Letter Quality

The Patient Education Materials Assessment Tool (PEMAT), developed by the Agency for Healthcare Research and Quality, supplies a validated instrument for scoring understandability and actionability of print materials. Facilities can apply the PEMAT to existing templates, identify specific deficits (word choice, lack of explicit steps, absence of visual hierarchy), and iterate until scores improve. Quality-improvement projects that combine readability reduction with PEMAT-guided redesign have produced large gains in both understandability and actionability scores for BI-RADS Category 0 recall letters. [7]

Patient and Operational Consequences

When the letter fails to convey a clear, actionable message, patients delay or forgo recommended diagnostic imaging. Incomplete follow-up contributes to later-stage diagnoses and measurable disparities by race, insurance status, and neighborhood disadvantage. Conversely, letters that meet the regulatory floor and then exceed it through literacy alignment, calibrated tone, and sequential reinforcement shorten the interval to resolution, reduce uncertainty for the patient, and lower the volume of lost-to-follow-up findings that surface in medical-outcomes audits.

Operational Implication and Leadership Question

The amended MQSA regulations effective September 10, 2024 established a uniform national baseline for content and timing. That baseline is necessary but not sufficient. Facilities that treat the lay result letter as a static compliance artifact forfeit the leverage that readable, actionable, and sequenced communication provides over patient behavior. The deeper mechanism is that the letter functions as the primary interface between clinical recommendation and patient action; its design therefore determines a non-trivial fraction of downstream diagnostic completion rates.

The leadership question is whether the facility will continue to stop at the single mandatory letter required by regulation, or whether it will treat sequential, literacy-optimized, and navigation-supported outreach as a core operational process that systematically converts every abnormal result into timely resolution.

---

References (AMA 11th edition)

1. US Food and Drug Administration. Important information: final rule to amend the Mammography Quality Standards Act (MQSA). Updated 2024. Accessed August 19, 2026. https://www.fda.gov/radiation-emitting-products/mammography-quality-standards-act-mqsa-and-mqsa-program/important-information-final-rule-amend-mammography-quality-standards-act-mqsa
2. Mammography Quality Standards Act. 88 FR 15126 (March 10, 2023) (codified at 21 CFR Part 900). Effective September 10, 2024. https://www.federalregister.gov/documents/2023/03/10/2023-04550/mammography-quality-standards-act
3. Electronic Code of Federal Regulations. 21 CFR 900.12(c)(2). Communication of mammography results to the patients. Accessed August 19, 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-I/part-900/subpart-B
4. US Food and Drug Administration. Facility resource for MQSA regulations going into effect on 9/10/2024 (guidance document). https://www.fda.gov/media/181152/download
5. Nguyen DL, Harvey SC, Oluyemi ET, Myers KS, Mullen LA, Ambinder EB. Impact of improved screening mammography recall lay letter readability on patient follow-up. J Am Coll Radiol. 2020;17(11):1429-1436. doi:10.1016/j.jacr.2020.07.006. https://pmc.ncbi.nlm.nih.gov/articles/PMC7390731/
6. Nguyen DL, Oluyemi E, Myers KS, Harvey SC, Mullen LA, Ambinder EB. Impact of telephone communication on patient adherence with follow-up recommendations after an abnormal screening mammogram. J Am Coll Radiol. 2020;17(9):1139-1148. doi:10.1016/j.jacr.2020.03.030. https://pubmed.ncbi.nlm.nih.gov/32353352/
7. Shoemaker SJ, Wolf MS, Brach C. Development of the Patient Education Materials Assessment Tool (PEMAT): a new measure of understandability and actionability for print and audiovisual patient information. Patient Educ Couns. 2014;96(3):395-403. doi:10.1016/j.pec.2014.05.027. Agency for Healthcare Research and Quality. The Patient Education Materials Assessment Tool (PEMAT) and user's guide. https://www.ahrq.gov/health-literacy/patient-education/pemat.html
8. Lippert RD Jr. The 30-60-90 day letter protocol: how continual written outreach improves mammography follow-up. Mammologix. August 17, 2026. https://mammologix.com/mammocommunicate/30-60-90-day-letter-protocol-mammography-follow-up
9. Lippert RD Jr. Determinants of patient compliance in mammographic follow-up notification letters. Mammologix. May 2, 2026. https://mammologix.com/mammocommunicate/determinants-patient-compliance-mammographic-follow-up-notification-letters